Back to Search Start Over

Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies

Authors :
Barbieri, L.
Verdoia, M.
Schaffer, A.
Suryapranata, H.
Luca, G. De
Barbieri, L.
Verdoia, M.
Schaffer, A.
Suryapranata, H.
Luca, G. De
Source :
Cardiovascular Drugs and Therapy; 611; 622; 0920-3206; 6; 30; ~Cardiovascular Drugs and Therapy~611~622~~~0920-3206~6~30~~
Publication Year :
2016

Abstract

Item does not contain fulltext<br />BACKGROUND: Patients with coronary artery disease who undergo stent implantation and have concomitant indication for long-term oral anticoagulation represent a considerable proportion of the overall population. To date there is still no consensus about the optimal antithrombotic strategy to choose in this kind of patients, due to the difficult balance between an increased risk of bleeding and thromboembolic complications. Therefore, the aim of this study was to perform a meta-analysis to evaluate the risk and benefits of triple antithrombotic therapy versus dual antithrombotic therapy in patients undergoing coronary stent implantation, requiring long-term oral anticoagulation. METHODS: We performed formal searches of PubMed, EMBASE, Cochrane central register of controlled trials and major international scientific session abstracts from January 1990 to September 2015 regarding the use of triple antithrombotic therapy (TT) versus dual therapy (DT) in patients undergoing percutaneous coronary stent implantation that required chronic oral anticoagulation. Data regarding study design, inclusion/exclusion criteria, number of patients, and selected endpoints was extracted by 2 investigators. Disagreements were resolved by consensus. RESULTS: Sixteen trials with a total of 21716 patients undergoing coronary stent implantation with indication to long term oral anticoagulation, were finally included. A total of 6950 received TT, whereas 14766 received DT alone. The follow-up period ranged from 180 to 730 days. Data regarding mortality were available in 21658 patients (99.7 %). All cause mortality was observed in 10.4 % patients in TT versus 16.3 % in DT (OR [95 % CI] =0.73 [0.66-0.80], p <0.001; p het <0.001). In addition, TT was associated with a reduced incidence of MI (6.4 versus 9.8 %, OR [95 % CI] = 0.74 [0.65-0.84], p < 0.001; phet < 0.001) and ischemic stroke (1.8 versus 3.9 %, OR [95 % CI] = 0.55 [0.45-0.68], p < 0.001; p het = 0.07). As expected, TT was associated wi

Details

Database :
OAIster
Journal :
Cardiovascular Drugs and Therapy; 611; 622; 0920-3206; 6; 30; ~Cardiovascular Drugs and Therapy~611~622~~~0920-3206~6~30~~
Publication Type :
Electronic Resource
Accession number :
edsoai.on1284119576
Document Type :
Electronic Resource